NICE
NICE Ltd.
NICE's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over NICE overall, supported by stronger fundamentals and stronger modeled upside.
NICE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
NICE's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
NICE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 14x | $94.12 | — |
| Cheap | 17x | $116 | +23% |
| Fair | 49x | $341 | +263% |
| Expensive | 76x | $522 | +454% |
Historical ranges are pointers, not guarantees.
NICE's PE is in its cheap range at 14x.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over NICE in the historical PE scenario, which offers more potential upside but is not a forecast.
NICE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
NICE has the edge over NVDA on the outlook, with more favorable profitability expectations.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
NICE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $6.90 | -18% |
| Q1 2026 | $8.43 | +18% |
| Q4 2025 | $9.67 | +43% |
| Q3 2025 | $8.80 | +36% |
| Q2 2025 | $8.37 | +40% |
| Q1 2025 | $7.17 | +29% |
| Q4 2024 | $6.76 | +33% |
| Q3 2024 | $6.46 | +31% |
NICE earned $6.90 per share over the past year, down 18% from the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over NICE on earnings, with more consistent year-over-year improvement.
NICE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $795.7M | +9.5% |
| Q1 2026 | $766.5M | +9.5% |
| Q4 2025 | $786.5M | +9% |
| Q3 2025 | $732M | +6.1% |
| Q2 2025 | $726.7M | +9.4% |
| Q1 2025 | $700.2M | +6.2% |
| Q4 2024 | $721.6M | +16% |
| Q3 2024 | $690M | +15% |
NICE's revenue has grown year over year every quarter since late 2020: $796M last quarter, up 9.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 14% | -8.3 points |
| Q1 2026 | 16% | -4.7 points |
| Q4 2025 | 22% | +1 points |
| Q3 2025 | 22% | +1.5 points |
| Q2 2025 | 22% | +2.7 points |
| Q1 2025 | 21% | +2.7 points |
| Q4 2024 | 21% | +1.7 points |
| Q3 2024 | 20% | +1.6 points |
NICE's operating margin was 14% last quarter, down 8.3 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over NICE on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over NICE on profitability, with a higher operating margin.
NICE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $117.3M | +204% |
| Q1 2026 | $169.4M | -36% |
| Q4 2025 | $156M | -31% |
| Q3 2025 | $163.6M | +24% |
| Q2 2025 | $38.6M | -74% |
| Q1 2025 | $264.6M | +16% |
| Q4 2024 | $225.1M | +40% |
| Q3 2024 | $131.7M | +28% |
NICE generated $606M in free cash flow over the past year, down 8.2% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over NICE on cash flow, with more consistent year-over-year improvement.
NICE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -1.2M shares |
| 1 year | -6% | -3.8M shares |
| 3 years | -11% | -7M shares |
| 5 years | -11% | -7.1M shares |
| Available history | -8.7% | -5.7M shares |
NICE has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $60.8M |
| Q1 2026 | $252.6M |
| Q4 2025 | $165.2M |
| Q3 2025 | $40.6M |
| Q2 2025 | $30.8M |
| Q1 2025 | $252.3M |
| Q4 2024 | $95.2M |
| Q3 2024 | $86.4M |
NICE spent $519M buying back its own shares over the past year, up 12% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
NICE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.2x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | 0.0x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | -0.1x | Net Cash |
NICE has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
NICE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.9 | Neutral |
| Stochastic | 24.3 | Neutral |
NICE's weekly RSI is 43 (neutral) and its Stochastic is 24 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
NICE PE vs Technology Sector
| Metric | NICE | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 28x | 51% below |
| PE % | 13 | 35 | 22 pts below |
NICE has the edge over NVDA on valuation relative to its sector.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
NICE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $110.2 | 15% below |
| 20 week MA | $104.5 | 9.9% below |
| 50 week MA | $105.3 | 11% below |
| 100 week MA | $128.5 | 27% below |
| 200 week MA | $162.8 | 42% below |
NICE is in a downtrend: it's below all five of its weekly moving averages, and 42% below its 200-week average.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has the edge over NICE on trend strength, trading above more of its moving averages.
NICE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $156.3 | $279.8 | +79% |
| 2021 | $279.8 | $306.4 | +9.5% |
| 2022 | $306.4 | $194.7 | -36% |
| 2023 | $194.7 | $199.5 | +2.5% |
| 2024 | $199.5 | $173.5 | -13% |
| 2025 | $173.5 | $112.7 | -35% |
| 2026 YTD | $112.7 | $94.1 | -16% |
NICE has finished lower in three of the last six years. It's down 16% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over NICE on returns for 2026, with the stronger performance.